Upgrade to SI Premium - Free Trial

Propanc Biopharma, Inc. (PPCB)

1.01 -0.01 (0.98%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (1/2/26 *Est.)

Latest Headlines

Propanc reports preclinical pancreatic cancer data for PRP drug candidate August 27, 2026 8:30 AM - StreetInsider Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit August 27, 2026 8:30 AM - Globe NewsWire Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit August 27, 2026 8:30 AM - StreetInsider Form DEF 14C Propanc Biopharma, Inc. For: Aug 20 August 21, 2026 6:02 AM - SEC Filing Propanc Biopharma begins prep for Phase 1b cancer therapy trial in Australia August 18, 2026 8:30 AM - StreetInsider Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP August 18, 2026 8:30 AM - StreetInsider Propanc Biopharma plans Phase 1b trial for cancer drug PRP August 12, 2026 8:32 AM - StreetInsider Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers August 12, 2026 8:30 AM - StreetInsider Propanc reports 90%+ tumor growth inhibition for PRP in pancreatic cancer August 6, 2026 8:31 AM - StreetInsider Propanc Biopharma reports preclinical data showing 90% tumor inhibition August 6, 2026 8:31 AM - StreetInsider Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models August 6, 2026 8:30 AM - StreetInsider Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Model August 6, 2026 8:30 AM - Globe NewsWire Propanc Biopharma completes $500K first tranche of share buyback August 5, 2026 8:30 AM - StreetInsider Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program August 5, 2026 8:30 AM - StreetInsider Form PRE 14C Propanc Biopharma, Inc. For: Aug 04 August 5, 2026 6:01 AM - SEC Filing Form EFFECT Propanc Biopharma, Inc. July 28, 2026 6:05 AM - SEC Filing Propanc publishes recombinant proenzyme study in peer-reviewed journal July 21, 2026 8:31 AM - StreetInsider Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal July 21, 2026 8:30 AM - StreetInsider Form S-1 Propanc Biopharma, Inc. July 17, 2026 5:31 PM - SEC Filing Form 8-K Propanc Biopharma, Inc. For: Jul 08 July 14, 2026 4:01 PM - SEC Filing Propanc Biopharma signs MOU with Avance Clinical for Phase 1 trial July 7, 2026 8:33 AM - StreetInsider Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd July 7, 2026 8:30 AM - StreetInsider Propanc Biopharma launches $5M share repurchase program July 2, 2026 8:30 AM - StreetInsider Propanc Biopharma Initiates $5.0 Million Share Repurchase Program July 2, 2026 8:30 AM - StreetInsider PROPANC Biopharma CEO visits European CDMO for PRP drug production June 16, 2026 8:45 AM - StreetInsider PPCB CEO visits European CDMO ahead of PRP drug manufacturing plan June 16, 2026 8:45 AM - StreetInsider Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study June 16, 2026 8:45 AM - Globe NewsWire Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study June 16, 2026 8:45 AM - StreetInsider Propanc Biopharma authorizes $5 million stock buyback program June 11, 2026 8:30 AM - StreetInsider Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program June 11, 2026 8:30 AM - StreetInsider Full Article List